Related Experiment Video

Updated: May 11, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Relapse-free rate with childhood acute lymphoblastic leukemia treated under the thai national protocol

Piangjit Tharnprisan1, Jiraporn Khiewyoo, Piporn Sripraya

  • 1Department of Biostatistics and Demography, Faculty of Public Health, Khon Kaen University, Khon Kaen, Thailand.

Asian Pacific Journal of Cancer Prevention : APJCP
|April 30, 2013
PubMed

Insights

Childhood acute lymphoblastic leukemia (ALL) treatment under the Thai national protocol showed improved relapse-free survival compared to previous methods. However, outcomes still lag behind developed nations, necessitating further treatment approach reviews.

Area of Science:

  • Pediatric Oncology
  • Hematology
  • Clinical Research

Background:

  • The Thai national protocol for childhood acute lymphoblastic leukemia (ALL) was implemented in 2006.
  • A systematic evaluation of treatment outcomes is crucial for protocol refinement.
  • This study assesses relapse-free survival in pediatric ALL cases managed under this protocol.

Purpose of the Study:

  • To evaluate the relapse-free survival (RFS) rates in children with ALL treated with the standard Thai national protocol.
  • To identify factors associated with relapse in pediatric ALL patients.
  • To compare treatment outcomes with international standards.

Main Methods:

  • A descriptive study involving 103 newly diagnosed pediatric ALL patients (0-15 years) from March 2006 to March 2011.
  • Patients were treated according to risk stratification within the Thai national protocol.
  • Kaplan-Meier and Cox proportional hazard models were used to analyze RFS and associated factors.

Main Results:

  • Complete remission was achieved in 83.5% of patients (86/103).
  • The 1, 3, and 5-year relapse-free survival rates were 93.0%, 84.5%, and 64.1%, respectively.
  • Age under 1 year was significantly associated with a higher risk of relapse (HR=6.0).

Conclusions:

  • Relapse-free survival in childhood ALL treated under the Thai national protocol at Srinagarind Hospital has improved.
  • Current outcomes remain suboptimal compared to those reported in developed countries.
  • Further review and potential modifications of the ALL treatment approach are warranted.
Abstract

More Related Videos

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...